ADMA shares rose 26.0% after earnings, as investors responded to 31% year-over-year ASCENIV growth, 71% corporate gross margin and substantial earnings growth. The quarter also showed continued pressure on BIVIGAM revenue, while management pointed to early signs of stabilization in end-user utilization.
ADMA Biologics shares dropped 18.9% following earnings due to continued top-line pressures on BIVIGAM amid intensified competitive dynamics and disruptive distributor ordering patterns, which overshadowed strong ASCENIV demand and margin expansion.
ADMA Biologics reported a strong third quarter of 2025, with total revenue reaching $134.2 million, showcasing solid sequential and year-over-year growth driven by record utilization of ASCENIV and operational advancements.